Previous close | 2.3400 |
Open | 3.1000 |
Bid | 3.2000 |
Ask | 3.2500 |
Strike | 140.00 |
Expiry date | 2024-07-19 |
Day's range | 2.9200 - 3.2000 |
Contract range | N/A |
Volume | |
Open interest | 2.56k |
Denmark faces a supply shortage for two doses of Novo Nordisk's Wegovy weight-loss drug in the coming months due to rising demand, the Danish Medicines Agency said on Monday. The hugely popular Wegovy is given by weekly injection and belongs to a class of drugs known as GLP-1 agonists originally developed to treat type 2 diabetes. There will be a shortage of Novo Nordisk's Wegovy Flextouch 1 milligram pen from late May to mid-June, the Danish medicines agency said in a statement.
Ozempic and Wegovy maker Novo Nordisk should be forced to cut the price of its obesity and diabetes wonder drugs, Bernie Sanders has said, claiming the current costs are “outrageously high”.
The company will collaborate with a biotech founded by Flagship Pioneering, the venture capital firm that created Moderna.